Pediatric population and pneumococcal disease prevention: spreading the news of a next-generation vaccine

The challenges

The Biopharmaceutical corporation has been producing marketing material about their FDA (the U.S. Food and Drug Administration) and ANVISA (the Brazilian National Health Surveillance Agency)-approved conjugate vaccine indicated for active immunization for the prevention of pneumonia and invasive disease caused by 20 Streptococcus pneumoniae serotypes in pediatric population.

​

That content should reach the Brazilian market and relevant Healthcare professional communities, sharing details regarding qualitative researches and highlighting the vaccine’s features, coverage, specifications and importance for protection against invasive pneumococcal disease.
 

​

The solution

Translation, localization and transcreation services.

The content
Leaflets, brochures, concepts and visuals content.

Leaflets, brochures, concepts and visuals content transcreated and translated from English into Brazilian Portuguese and linguistically appropriate for use in the Brazilian market and for relevant Healthcare professional communities, spreading the news about a next-generation vaccine with the broadest serotype coverage available against pneumococcal disease.

That eventually would help to mitigate the risk of such a serious condition for the pediatric population.

Moreover, the content in Brazilian Portuguese has been part of the Biopharmaceutical corporation’s successful market expansion strategy for their vaccine.